Nimodipine in migraine: clinical efficacy and endocrinological effects

R. Formisano, P. Falaschi, R. Cerbo, A. Proietti, T. Catarci, R. D'Urso, C. Roberti, V. Aloise, F. Chiarotti, A. Agnoli

Research output: Contribution to journalArticle

Abstract

Serum prolactin is increased during chronic flunarizine treatment of patients suffering from migraine. In order to clarify the role of calcium in control of the secretion of anterior pituitary hormones, a study has now been made of the effects of chronic nimodipine and propranolol treatment of migraine patients on prolactin (PRL), luteinizing hormone (LH) and growth hormone (GH) levels. 11 patients were treated with nimodipine and 8 with propranolol for four months. A statistically significant reduction in the frequency of the attacks was demonstrated in both groups. No significant change was found in the hormones levels during nimodipine treatment.

Original languageEnglish
Pages (from-to)69-71
Number of pages3
JournalEuropean Journal of Clinical Pharmacology
Volume41
Issue number1
DOIs
Publication statusPublished - Jul 1991

Keywords

  • adverse effects
  • growth hormone
  • luteinizing hormone
  • Migraine
  • nimodipine
  • prolactin
  • propranolol

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Nimodipine in migraine: clinical efficacy and endocrinological effects'. Together they form a unique fingerprint.

  • Cite this

    Formisano, R., Falaschi, P., Cerbo, R., Proietti, A., Catarci, T., D'Urso, R., Roberti, C., Aloise, V., Chiarotti, F., & Agnoli, A. (1991). Nimodipine in migraine: clinical efficacy and endocrinological effects. European Journal of Clinical Pharmacology, 41(1), 69-71. https://doi.org/10.1007/BF00280110